Skip to main content

Table 1 Clinico-pathological data

From: Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer

 

Biobank 1

Biobank 2

Clinical features

Control patients (N)

Invasive cancer (C)

Control patients (N)

Invasive cancer (C)

Gender

 Female

12 (57%)

9 (47%)

24 (52%)

16 (59%)

 Male

9 (43%)

10 (53%)

22 (48%)

11 (41%)

Age (years, Median [range])

52 [19–64]

69 [51–87]

52 [23–81]

66 [27–90]

Weight (kg, Median [range])

70 [48–115]

70 [50–100]

71 [42–130]

65 [40–89]

Size (cm, Median [range])

164 [155–193]

168 [157–182]

168 [145–187]

165 [153–185]

Cancer stage

 I

 

2 (11%)

 

4 (15%)

 II

 

5 (26%)

 

10 (37%)

 III

 

5 (26%)

 

7 (26%)

 IV

 

7 (37%)

 

6 (22%)

Tumor location

 Right colon

 

11 (60%)

 

N/A

 Left colon

 

8 (40%)

 

N/A

  1. Patients were selected randomly from two collections and included for the validation of FXIII by ELISA and AP-F13A1 by PRM assays. For cancer patients, they were classified according to cancer’s stage (I, II, III, IV) and the location of the primary tumor